Changing patients' lives

ReNeuron Group plc

Annual Report and Accounts 2019

Our vision is
to deliver life-changing
therapies to patients

As a leader in cell-based therapeutics, we develop proprietary allogeneic stem cell technology platforms to address significant areas of unmet medical need. Our therapeutic portfolio is comprised of two clinical stage candidates: hRPC and CTX stem cell therapies. In addition we are developing an exosome technology platform.

Group at a glance

hRPC stem cell therapy

Our hRPC stem cell therapy could change the lives of patients suffering from retinitis pigmentosa (RP).

What are hRPCs?

Allogeneic, cryopreserved cell-based therapy for treatment of retinal diseases.

What can they do?

Human retinal progenitor cells (hRPCs) have the ability to differentiate into all of the nerve cells and nerve support cells of the retina.

How it is used

Our therapy is initially targeting the inherited retinal degenerative disease, retinitis pigmentosa, by implantation of our cell therapy into the retina. 

CTX stem cell therapy

Our CTX stem cell therapy will change the lives of patients suffering from stroke disability.

What are CTX stem cells?

Allogeneic, cryopreserved, immortalised neural stem cells for treatment of stroke
disability.

What can they do?

CTX stem cells have the ability to differentiate into a repertoire of specific nerve and nerve support cells.

How it is used

Our cell therapy is directly injected into the brain near to the area damaged by the stroke.

CTX-derived exosomes

Our CTX derived exosomes could change the lives of patients where current treatment options are limited.

What are CTX-derived exosomes?

These are nano-sized packages of information released by CTX cells.

What can they do?

Therapeutic agents can be loaded to our exosomes and potentially be used to treat a host of poorly met medical needs.

How it is used

CTX-derived exosomes can be delivered either locally or systemically depending upon the desired final destination.

Our current pipeline

Programme

Indication

Pre-clinical

Phase 1

Phase 2

Next Milestone

hRPCs

Retinitis Pigmentosa

Top line Phase 1/2a data read out expected Q4 2019

CTX cells

Stroke Disability

PISCES III, pivotal, multi-centre U.S. Phase 2b study, data read out expected Q4 2020

Exosomes

Drug Delivery / Therapy

Collaboration / Partnering deals targeted

hRPCs Retinitis Pigmentosa

CTX cells Stroke Disability

Exosomes Drug Delivery / Therapy

Pre-clinical
Phase 1
Phase 2

Next Milestone

hRPCs

Top line Phase 1/2a data read out expected Q4 2019

CTX cells

PISCES III, pivotal, multi-centre U.S. Phase 2b study, data read out expected Q4 2020

Exosomes

Collaboration / Partnering deals targeted

Woman looking into microscope

A year of progress towards changing patients' lives

hRPC stem cell therapy:

Strongly positive preliminary efficacy data from the first three Phase 2a patients in ongoing US Phase 1/2a clinical trial in retinitis pigmentosa (RP).

CTX stem cell therapy candidate for stroke disability:

We continued to progress the clinical development of our CTX cell therapy as patient dosing commenced in January 2019

Exosome nanomedicine platform:

We are exploring the use of our exosome platform as a potential drug delivery vehicle.

Winner of the Breakthrough of the Year award

In June 2019, we won the 'Breakthrough of the Year' award at the 2019 European Mediscience Awards. This award underlines the strong clinical development and commercial progress we have made over the past year.

Performance

Chairman’s statement

ReNeuron continues to make sound progress across its therapeutic programmes.

John Berriman

Non-executive Chairman

Chief Executive Officer’s review of performance

The past year has been a transformational one for ReNeuron.

Olav Hellebø

Chief Executive Officer